After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Becoming a blockbuster in its third full year on the market put Gilead’s cancer treatment Trodelvy on a course to potentially justify the company’s $21 billion ...

Through the five-year initiative, the Merck Foundation will provide grants to 11 organizations working to improve health outcomes in places where timely access to cardiovascular care is a challenge.

A proposed buyout of Bavarian Nordic by a private equity consortium didn’t win over enough shareholder support, laying to ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...